SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

SLAP is trending as community members rally around the project's real-world partnerships, including a sponsored MMA fighter. The community emphasizes their daily grind and commitment to building a recognizable brand within sports culture, attracting attention and engagement. Bullish sentiment and frequent mentions across social media platforms contribute to its current momentum.

What makes MOG an absolute game-changer is our relentless dedication to memes and viral brilliance! We don't settle for mediocrity; we plunge into the realm of sheer awesomeness! Our community is a powerhouse of meme warriors, unleashing an unstoppable onslaught of viral memes that'll leave you in awe and stitches!  We're not here to play games; we're here to dominate! MOG is all about pushing the boundaries, smashing through barriers, and leaving our competitors eating our dust! Our passion for humor burns like an inferno, and we won't rest until the entire internet bows down to our meme supremacy!  And our community? It's a brotherhood, an unyielding powerhouse of support and camaraderie! When you're part of MOG, you're part of an unstoppable force, a family forged by the fire of meme revolution!  So, if you're ready to be part of the most intense, mind-bending memecoin movement ever conceived, then buckle up, strap in, and brace yourself! MOG is here to claim the throne, and we're taking no prisoners! Get ready to witness meme history in the making!

 MOG Coin

MOG Coin is trending as community members express excitement for a potential run, with some suggesting it could follow the path of other successful meme coins. Discussions revolve around holding strategies, accumulation, and anticipation of exchange listings.  However, some users are wary, alleging it to be a scam.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending as traders discuss its bullish bias, with some anticipating a rise towards May highs. Community members are actively debating potential pullbacks and near-term price targets. Bullish sentiment remains as long as it holds above the $1.20 support level.

Velo Labs is building a unique federated credit exchange network. This network is powered by the Velo Protocol, which is a blockchain financial protocol enabling digital credit issuance and borderless asset transfers for businesses using a smart contract system. The project's core mission is to enable partners to safely and securely transfer value between each other in a timely and transparent way. To do this, the Velo Protocol enables its partners to issue digital credits via a smart contract layer, using the Stellar Consensus Protocol to process and settle transactions. Within its ecosystem, the Velo Protocol enables multiple business use cases that are all based on its core function: issuing collateral-backed digital credits, which correspond to any fiat currency that can be used for frictionless value transfer.

Velo Labs

Velo Labs ($VELO) is trending as traders discuss its potential as the 'XRP of Asia' and its focus on the Asian remittance market. Community members are actively speculating on potential exchange listings and future price targets, while also highlighting its underlying technology built on the Stellar network. Some traders are accumulating $VELO, citing its undervaluation and potential for significant gains, while others express concerns about its price action and volatility.

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin is trending as the community debates its potential amid mixed sentiment; some see it as undervalued with future growth potential, while others express frustration over its historical performance and question its utility. Discussions include potential price targets, its role in decentralized storage, and comparisons to other cryptocurrencies. Some investors are taking advantage of the price dip to accumulate more coins, while others are considering selling.

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Fresenius Medical Care AG - ADR

Fresenius Medical Care AG & Co. KGAA

Fresenius Medical Care ($FMS) is trending due to discussions around DefenCath's potential impact on profitability and mortality benefits, particularly after Q3 reports. The community debates the implications of CMS's TDAPA decision and DaVita's ($DVA) approach to infection prevention compared to Fresenius. Investors are also weighing $FMS's growth prospects against competitors like CVS Health ($CVS), considering acquisitions, partnerships, and global presence amid rising costs.

The Williams Cos., Inc. operates as an energy infrastructure company, which explores, produces, transports, sells and processes natural gas and petroleum products. It operates through the following segments: Transmission and Gulf of Mexico, Northeast G&P, and West. The Transmission and Gulf of Mexico segment consists of interstate natural gas pipelines, the Transco and Northwest Pipelines, as well as natural gas gathering and processing and crude oil production handling and transportation assets in the Gulf Coast region. The Northeast G&P segment includes midstream gathering, processing, and fractionation businesses in the Marcellus Shale region primarily in Pennsylvania and New York, and the Utica Shale region of eastern Ohio. The West segment consists of gas gathering, processing, and treating operations in the Rocky Mountain region of Colorado and Wyoming, the Barnett Shale region of north-central Texas, the Eagle Ford Shale region of south Texas, the Haynesville Shale region of northwest Louisiana, and the Mid-Continent region which includes the Anadarko, Arkoma, and Permian basins. The company was founded by David Williams and Miller Williams in 1908 and is headquartered in Tulsa, OK.

Williams Cos Inc

Williams Companies is gaining attention as it approaches its earnings date, with analysts anticipating a strong performance fueled by Transco pipeline growth. The community is weighing potential cost pressures against the backdrop of positive earnings forecasts. Recent analyst upgrades and industry growth in the midstream energy sector, particularly natural gas infrastructure, are contributing to the increased interest.

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

Argen X SE - ADR

Argenx

Argenx ($ARGX) is trending due to positive Q3 earnings, exceeding both EPS and revenue expectations, driving optimism among investors. Bullish sentiment is further fueled by multiple analyst buy recommendations and high price targets, with the community actively discussing the potential for the stock to reach $900+ soon. The company's pipeline and potential buyout are also hot topics.

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Exact Sciences Corp.

EXAS is trending as investors monitor upcoming earnings and anticipate the impact of new product launches like Cologuard Plus. Community discussions are focused on the potential for growth in the cancer diagnostics sector and the company's ability to compete with other genomics players. Recent insider buying is being interpreted as a bullish signal, despite some concerns about market sentiment.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is trending as investors debate its future following recent price volatility and an earnings report, with some citing strong growth metrics and others expressing concern over short interest and market conditions. Community members are actively discussing potential entry points, upcoming earnings, and comparing Sezzle to competitors within the BNPL sector. The stock's price action and high short interest are key points of focus for traders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal

Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.

Rapport Therapeutics, Inc. (RAPP) on Monday said that a mid-stage clinical trial of RAP-219 in patients with drug-resistant focal onset seizures demonstrated a statistically significant reduction in long episodes over the 8-week treatment period.RAP-219 also <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.rapportrx.com/news-releases/news-release-details/rapport-announces-positive-topline-results-phase-2a-clinical">demonstrated</a> a statistically significant and clinically meaningful reduction in seizures accompanied by physical signs compared with baseline in the study, the company said, while adding that it plans to advance the investigational therapy into two late-stage trials in the third quarter of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RAPP">RAPP stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels. Shares of the company traded 204% higher in the pre-market session at the time of writing.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_8_06_25_AM_png_a5918d7983.webp" alt="RAPP's Sentiment Meter and Message Volume as of 8:15 a.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>RAPP's Sentiment Meter and Message Volume as of 8:15 a.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded optimistic, saying the update is ‘great news.’<stembedurl>https://stocktwits.com/Mushichka/message/627808704</stembedurl>Another user, however, expressed doubts about whether the data warrants the massive rally.<stembedurl>https://stocktwits.com/Trader_Tom/message/627805877</stembedurl>H.C. Wainwright subsequently raised its price target on Rapport to $34 from $31 while keeping a ‘Buy’ rating on the shares. The firm states that RAP-219 surpassed its "most bullish expectations" and added that the data provides "unimpeachable evidence" of the drug's effect, offering "strong evidence that it has the potential to become a mainstay" in the treatment of focal onset seizures. The firm increased its probability of success for oral RAP-219 to 66% and its peak revenue estimate to $766 million, up from $613 million.Focal onset seizures are seizures that begin in one area of one brain hemisphere, causing symptoms that typically affect one side of the body or are limited to a specific sensation, emotion, or movement. In the trial, Rapport enrolled 30 patients, 18 men and 12 women, with focal onset seizures who had an implanted RNS System, a brain simulation device for drug-resistant focal epilepsy. The patients received 0.75 mg of RAP-219 oral tablets daily for 5 days, followed by 1.25 mg of RAP-219 oral tablets daily for the remainder of the 8-week treatment period.During the treatment period, over 85% patients achieved more than or equal to 30% reduction in long episodes from baseline, the company said, while 72% achieved more than or equal to 50% reduction. Twenty-four patients also achieved seizure freedom, the company said. Reduction in long episodes (LEs) is an objective electrographic biomarker for clinical seizure reduction, it said.RAP-219 was generally well-tolerated in the trial, with the majority of treatment-emergent adverse events being mild and a low discontinuation rate, the company added.Rapport plans to hold an end-of-mid-stage trial meeting with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025. The company also expects to present additional efficacy analyses and 8-week follow-up results in 2026 and to initiate a trial to evaluate the long-term safety of the therapy in patients by the end of 2025. RAP-219 is also being evaluated in bipolar mania and diabetic peripheral neuropathic pain.RAPP stock is down 19% this year and approximately 27% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pnc-to-buy-colorado-first-bank-for-4-1-b-in-push-to-bolster-national-reach/chwWxbxRdrR">PNC To Buy Colorado’s FirstBank for $4.1B In Push To Bolster National Reach: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened

The company said that it now plans to advance the investigational therapy into two late-stage trials in the third quarter of 2026. 

Equity

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

RAPP
Rapport Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RAPP News

RAPPRapport Therapeutics Inc